Oncolytics Biotech (NASDAQ:ONCY) CFO Kirk Look Acquires 12,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY) CFO Kirk Look acquired 12,000 shares of the stock in a transaction on Thursday, February 12th. The stock was bought at an average price of $0.84 per share, with a total value of $10,080.00. Following the transaction, the chief financial officer directly owned 287,515 shares of the company’s stock, valued at approximately $241,512.60. The trade was a 4.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oncolytics Biotech Stock Performance

NASDAQ:ONCY opened at $0.83 on Friday. Oncolytics Biotech Inc. has a fifty-two week low of $0.33 and a fifty-two week high of $1.51. The firm has a market cap of $88.60 million, a PE ratio of -2.98 and a beta of 0.99. The business has a 50 day moving average price of $0.98 and a 200-day moving average price of $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. Research analysts predict that Oncolytics Biotech Inc. will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Oncolytics Biotech in the 3rd quarter worth approximately $535,000. Seeds Investor LLC increased its holdings in Oncolytics Biotech by 17.8% in the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after buying an additional 33,826 shares in the last quarter. Tocqueville Asset Management L.P. bought a new stake in shares of Oncolytics Biotech in the fourth quarter worth approximately $63,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the 4th quarter valued at $44,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of Oncolytics Biotech during the 4th quarter valued at about $30,000. 6.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ONCY. Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Zacks Research raised shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. HC Wainwright boosted their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oncolytics Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.